Vikas Sinha
CIK 1337845 · Chief Financial Officer · last filed 2026-04-20
Vikas Sinha is a Chief Financial Officer who has filed 162 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing shows the insider sold $516.1K of SRRK on Apr 20, 2026. Across all open-market trades the lifetime net is −$4.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $32.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$32.63M
3
162
-$4.66M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SRRK | Chief Financial Officer | 619,856 | $52.64 | $32.63M | -$1.23M | 5 | 2026-04-20 |
| Verona Pharma plc (VRNA) Delisted | Director | 0 | $106.91 | $0 | -$3.18M | 12 | 2025-10-08 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | See Remarks | 774,118 | $9.81 | $7.59M | -$246.5K | 40 | 2025-02-24 |
Recent Filings
162 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-20 | SRRK | Sell (S) | −10,410 | -$516.1K | EDGAR |
| 2026-02-11 | SRRK | Grant (A) | +47,021 | $0 | EDGAR |
| 2026-01-15 | SRRK | Sell (S) | −16,755 | -$715.4K | EDGAR |
| 2025-10-08 | Verona Pharma plc (VRNA) Delisted | Mixed | −94,112 | $0 | EDGAR |
| 2025-08-05 | Verona Pharma plc (VRNA) Delisted | Mixed | +19,672 | -$56.9K | EDGAR |
| 2025-05-22 | Verona Pharma plc (VRNA) Delisted | Mixed | — | -$1.42M | EDGAR |
| 2025-05-22 | Verona Pharma plc (VRNA) Delisted | Mixed | — | -$1.20M | EDGAR |
| 2025-05-20 | — | Notice (144) | −20,000 | -$1.45M | EDGAR |
| 2025-05-06 | SRRK | Grant (A) | — | $0 | EDGAR |
| 2025-05-01 | Verona Pharma plc (VRNA) Delisted | Mixed | — | -$150.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.